Drugs that contain Selumetinib Sulfate
1. List of Koselugo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8178693 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(a month from now) | |
| US7425637 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Apr, 2024
(1 year, 2 months from now) | |
| US9562017 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(3 years from now) | |
| US9156795 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity (ODE) | Apr 10, 2027 |
NCE-1 date: April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)
Dosage: CAPSULE;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic